Leukopenia in Kidney Transplant Patients With the Association of Valganciclovir and Mycophenolate Mofetil
نویسندگان
چکیده
منابع مشابه
Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil.
Cytomegalovirus (CMV) is the most common viral infection after transplantation. Valganciclovir (VGC) is established for prophylaxis and treatment of CMV infections, but leukopenia which appears in 10% to 13% (severe in 4.9%) is the principal side effect. We have recently noted an increased incidence of leukopenia and severe neutropenia among our renal transplant patients and thought to identify...
متن کاملUnexpected rate of severe leucopenia with the association of mycophenolate mofetil and valganciclovir in kidney transplant recipients.
Here, we report on a patient with a gram-negative CAPDrelated peritonitis presumably caused by an ascending infection due to fallopian tube capture of the CAPD catheter. An 81-year-old woman with coronary heart disease and end-stage renal disease as a consequence of diabetes mellitus underwent an uncomplicated surgical insertion of a Tenckhoff catheter. After 2 weeks, CAPD was started without d...
متن کاملthe past hospitalization and its association with suicide attempts and ideation in patients with mdd and comparison with bmd (depressed type) group
چکیده ندارد.
Mycophenolate mofetil-related pancolitis in a kidney transplant recipient.
Gastrointestinal adverse effects are common with mycophenolate mofetil administration, especially diarrhea. We report a case of mycophenolate mofetil-related colitis in a kidney transplant recipient. Colonoscopy revealed an ulcerative diffuse colitis. The colonoscopic biopsy specimen showed mild crypt distortion, accompanied by cryptitis and focal graft-versus-host disease like changes. The pa...
متن کاملPharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients.
BACKGROUND AND OBJECTIVES The introduction of mycophenolate mofetil has improved graft survival after organ transplantation; however, its use may be limited by important adverse effects. For overcoming these problems, an enteric-coated formulation of mycophenolate sodium has been developed, but pharmacokinetic data of mycophenolic acid release from this formulation are scanty. DESIGN, SETTING...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Transplantation Proceedings
سال: 2008
ISSN: 0041-1345
DOI: 10.1016/j.transproceed.2008.02.048